First Cheque with Cheryl Mack & Maxine Minter 
About Paul Kelly
Dr Paul Kelly is co-founder and venture partner at OneVentures, an Australian venture capital firm, where he leads the healthcare and biotechnology practice and chairs the investment committee for its Healthcare Fund III. He trained as an endocrinologist at St Vincent's Hospital Sydney before moving into biotechnology, co-founding Gemini Genomics and leading its Nasdaq listing at a US$250 million valuation ahead of its merger with Sequenom. He later served as chief executive of Orchid Cellmark, lifting its valuation tenfold, and now sits on the board of heart-device maker BiVACOR. On First Cheque, he discussed navigating biotech investing as a syndicate.
- Talks about
- Fundraising, Health & Biotech, Venture Capital
In conversation.
1 episode
First Cheque with Cheryl Mack & Maxine Minter The path so far.
- Now
Co-Founder & Venture Partner · OneVentures
- Earlier · Scale-up
CEO · Orchid Cellmark (Nasdaq: ORCH)
- Earlier · Startup
Co-founder · Gemini Genomics (Nasdaq: GMNI)
- Earlier · Startup
Co-founder · Agamatrix
- Earlier · Startup
Co-founder · Atomera (Nasdaq: ATMR)
- Earlier
Researcher/Endocrinologist · St Vincent's Hospital, Sydney
Sources: one-ventures.com.au
OneVentures on Day One
OneVentures is a Sydney venture capital firm that invests in later-stage technology and healthcare companies.
2 people · 2 episodes
Across the network.
Spot something wrong? Suggest a correctionUpdated 25 September 2026
Be part of
the conversation.
Put your brand alongside the voices founders, investors and operators come to hear.
Explore sponsorshipProduced by W2D1 Media
Want a show of your own?
W2D1 Media — the team behind the Day One Network, which helped build Blackbird Ventures' Wild Hearts — builds and produces podcasts for funds, founders and operators. If you want a show built around your brand, let's talk.
